Melanoma vaccine study pulled before it began
NCT ID NCT01861938
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This study aimed to test a genetically modified tumor cell vaccine designed to boost the immune system against melanoma in patients at high risk of recurrence or with low residual disease. It was planned for adults with specific tissue types and certain stages of melanoma. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK HLA-A2+ MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.